Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Operating Expenses (2016 - 2025)

Traws Pharma (TRAW) has disclosed Operating Expenses for 14 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 52.81% to $4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.6 million, a 86.86% decrease, with the full-year FY2024 number at $142.6 million, up 594.8% from a year prior.
  • Operating Expenses was $4.1 million for Q3 2025 at Traws Pharma, up from $4.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $123.4 million in Q2 2024 to a low of $3.8 million in Q4 2021.
  • A 5-year average of $11.2 million and a median of $4.7 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 2544.2% in 2024, then plummeted 96.77% in 2025.
  • Traws Pharma's Operating Expenses stood at $3.8 million in 2021, then soared by 51.61% to $5.8 million in 2022, then decreased by 21.97% to $4.5 million in 2023, then rose by 18.06% to $5.3 million in 2024, then fell by 23.98% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Operating Expenses are $4.1 million (Q3 2025), $4.0 million (Q2 2025), and $5.3 million (Q1 2025).